(0.32%) 5 116.44 points
(0.32%) 38 364 points
(0.37%) 15 987 points
(-0.98%) $83.03
(5.25%) $2.02
(0.32%) $2 354.70
(0.50%) $27.67
(4.12%) $960.10
(-0.27%) $0.932
(-0.46%) $10.97
(-0.58%) $0.796
(1.66%) $93.40
@ $45.15
発行日: 15 2月 2024 @ 05:24
リターン: -10.34%
前回のシグナル: 2月 15 - 01:15
前回のシグナル:
リターン: -2.59 %
Live Chart Being Loaded With Signals
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs...
Stats | |
---|---|
本日の出来高 | 175 690 |
平均出来高 | 1.16M |
時価総額 | 2.71B |
EPS | $0 ( 2024-02-13 ) |
次の収益日 | ( $0.470 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -269.87 |
ATR14 | $0.0320 (0.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-12 | Buechler Kenneth F | Buy | 9 041 | Common Stock |
2024-04-12 | Buechler Kenneth F | Sell | 9 041 | Non-Qualified Stock Option |
2024-03-28 | Iskra Michael S. | Buy | 4 925 | Common Stock |
2024-03-28 | Iskra Michael S. | Sell | 1 773 | Common Stock |
2024-03-28 | Iskra Michael S. | Sell | 4 925 | Restricted Stock Units |
INSIDER POWER |
---|
45.41 |
Last 100 transactions |
Buy: 322 615 | Sell: 120 021 |
ボリューム 相関
Quidel Corp 相関 - 通貨/商品
Quidel Corp 財務諸表
Annual | 2023 |
収益: | $2.99B |
総利益: | $1.28B (42.87 %) |
EPS: | $-0.150 |
FY | 2023 |
収益: | $2.99B |
総利益: | $1.28B (42.87 %) |
EPS: | $-0.150 |
FY | 2022 |
収益: | $3.27B |
総利益: | $1.94B (59.28 %) |
EPS: | $9.66 |
FY | 2021 |
収益: | $1.70B |
総利益: | $1.27B (74.82 %) |
EPS: | $16.74 |
Financial Reports:
No articles found.
Quidel Corp
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。